Clinical Trials at Duke Comprehensive Cancer Center

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Carolyn Andrews, RN or Ann-Marie Peters, RN via phone at (919) 681-4768 or fax at (919) 684-8926.

Trial Phase Lung Cancer
00014547 III CALGB 30607: Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced,
00017361 I Phase I Dose Escalation Study of Accelerated Fractionation With Esophageal Sparing Using Intensity-Modulated Radiation Therapy for Locally-Advanced Thoracic Malignancies Including a Prospective Assessment of Esophageal Motion and Radiation-Induced Esopha
00008303 II Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
00004682 II Dose-Dense Induction/Neoadjuvant Chemotherapy in the Treatment of Patients with Locally-Advanced Non-small cell Lung Cancer with Additional Genomic Analyses to Identify Signatures Predicitive of Chemotherapy Response
00004599 II Phase II Prospective Study Evaluating the Role of Pemetrexed Plus Gemcitabine Chemotherapy for Chemo-Naive Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy
00013056 II CALGB 30406 A Phase II Randomized Study of OSI-774 (Erlotinib) with or without Carboplatin/Paclitaxel in Patients with Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers
8076 II Phase II Randomized Study of CP-868,596 in Combination with Docetaxel and of Docetaxel Alone in Patients with Stage IIIB of IV Non-Small Cell Lung Cancer, Preceded by a Phase 1B Dose-Finding, Safety and Tolerability Study of the Combination in All Solid T
00011896 III A Phase III, Randomized, Double-Blind, Multicenter Study to Assess the Efficacy of Docetaxel (Taxotere) in Combination with ZD6474 (Zactima) verses Docetaxel (Taxotere) in Combination with Placebo in Patients with Locally Advanced or Metastatic (Stage III
Duke Comprehensive Cancer Center Accolades